OraSure Launches HEMAcollect PROTEIN Blood Collection Tube for Proteomic Research.
ByAinvest
Thursday, Jul 10, 2025 7:09 am ET1min read
OSUR--
The HEMAcollect●PROTEIN BCT is powered by ProteoPrecision™ technology, which minimizes hemolysis and platelet activation, ensuring the sample accurately reflects the body's state at the time of collection. This innovation addresses the limitations of general blood collection tubes, which often require refrigeration and have shorter stabilization periods [1].
The device is compatible with a broad range of proteomic technologies, including mass spectrometry, immunoassays, and high-throughput affinity-based platforms. This versatility makes it suitable for various research applications, such as oncology, neurology, cardiology, and metabolic disorders [1].
OraSure Technologies anticipates that the HEMAcollect●PROTEIN BCT will deliver operational and financial efficiencies for proteomic researchers. The ability to store and transport samples at ambient temperature simplifies workflows and reduces the need for specialized refrigeration equipment [1].
The launch of the HEMAcollect●PROTEIN BCT is part of OraSure Technologies' commitment to enhancing the quality of insights for researchers through innovative sample management solutions [1].
References:
[1] https://www.globenewswire.com/news-release/2025/07/10/3113127/11732/en/OraSure-Launches-Novel-Blood-Collection-Device-for-Proteomic-Research.html
OraSure Technologies has launched HEMAcollect●PROTEIN, an evacuated blood collection tube designed to preserve and stabilize plasma proteins in whole blood for up to seven days. The product is intended for research use only and is expected to provide operational and financial efficiencies for proteomic researchers while supporting the generation of high-quality data. The HEMAcollect●PROTEIN BCT can be stored and transported at ambient temperature, addressing limitations of general blood collection tubes.
OraSure Technologies, Inc. (NASDAQ: OSUR) has introduced a novel blood collection device, HEMAcollect●PROTEIN, designed to address the challenges faced by proteomic researchers. The device, developed by the company's subsidiary DNA Genotek, is an evacuated blood collection tube (BCT) that can preserve and stabilize plasma proteins in whole blood for up to seven days at ambient temperature [1].The HEMAcollect●PROTEIN BCT is powered by ProteoPrecision™ technology, which minimizes hemolysis and platelet activation, ensuring the sample accurately reflects the body's state at the time of collection. This innovation addresses the limitations of general blood collection tubes, which often require refrigeration and have shorter stabilization periods [1].
The device is compatible with a broad range of proteomic technologies, including mass spectrometry, immunoassays, and high-throughput affinity-based platforms. This versatility makes it suitable for various research applications, such as oncology, neurology, cardiology, and metabolic disorders [1].
OraSure Technologies anticipates that the HEMAcollect●PROTEIN BCT will deliver operational and financial efficiencies for proteomic researchers. The ability to store and transport samples at ambient temperature simplifies workflows and reduces the need for specialized refrigeration equipment [1].
The launch of the HEMAcollect●PROTEIN BCT is part of OraSure Technologies' commitment to enhancing the quality of insights for researchers through innovative sample management solutions [1].
References:
[1] https://www.globenewswire.com/news-release/2025/07/10/3113127/11732/en/OraSure-Launches-Novel-Blood-Collection-Device-for-Proteomic-Research.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet